Immutep Announces Expansion of Part A of TACTI-002 Phase II Clinical Trial due to Positive Interim Data
• Requisite clinical responses achieved in cohort 1 of Part A (1st line NSCLC) of TACTI-002 Phase II clinical trial to allow for recruitment of cohort 2
• Recruitment of cohort 2 of Part A of TACTI-002, additional 19 patients, will begin shortly
• Recruitment of the first cohorts of parts B and C continues
• Data from the ongoing TACTI-002 Phase II clinical trial will be presented at the 34th Annual Meetingof the Society for Immunotherapy of Cancer (SITC) in November 2019
Great news !
2.6c here we set
- Forums
- ASX - By Stock
- IMM
- Ann: Immutep expands Part A of TACTI-002 due to positive data
Ann: Immutep expands Part A of TACTI-002 due to positive data, page-3
-
- There are more pages in this discussion • 64 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
31.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $458.1M |
Open | High | Low | Value | Volume |
31.5¢ | 32.0¢ | 31.0¢ | $306.8K | 972.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 178587 | 31.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
32.0¢ | 44597 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 178587 | 0.315 |
20 | 548855 | 0.310 |
15 | 203289 | 0.305 |
22 | 459095 | 0.300 |
7 | 125083 | 0.295 |
Price($) | Vol. | No. |
---|---|---|
0.320 | 44597 | 1 |
0.325 | 69516 | 3 |
0.330 | 214747 | 5 |
0.335 | 199036 | 6 |
0.340 | 529176 | 4 |
Last trade - 16.10pm 07/10/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |